{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:07:51Z","timestamp":1791432471058,"version":"4.3.3"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ijrobp.2021.07.1716","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T23:35:00Z","timestamp":1628724900000},"page":"317-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Radiation Therapy Across Pediatric Hodgkin Lymphoma Research Group Protocols: A Report From the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8768-3577","authenticated-orcid":false,"given":"Matthew D.","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Terezakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Gallop-Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Flerlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika L.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0001","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/1097-0142(197508)36:2+<796::AID-CNCR2820360825>3.0.CO;2-N","article-title":"The management of Hodgkin's disease","volume":"36","author":"Kaplan","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0002","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma\u2014A report from the Children's Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0003","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1001\/jamaoncol.2018.5911","article-title":"Association of combined modality therapy vs chemotherapy alone with overall survival in early-stage pediatric Hodgkin lymphoma","volume":"5","author":"Jhawar","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/pbc.20546","article-title":"Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study","volume":"46","author":"Tebbi","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2006.08.4772","article-title":"Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease","volume":"25","author":"Donaldson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0006","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1200\/JCO.2002.03.051","article-title":"Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation","volume":"20","author":"Friedmann","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0007","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2004.02.139","article-title":"Risk-adapted, combined-modality therapy with VAMP\/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease","volume":"22","author":"Hudson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0008","first-page":"605","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood. 2009;114:2051-2059","volume":"128","author":"Schwartz","year":"2016","journal-title":"Erratum in: Blood"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0009","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: The GPOH-HD-2002 study","volume":"28","author":"Mauz-K\u00f6rholz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0010","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/COC.0000000000000294","article-title":"ACR Appropriateness Criteria\u00ae Hodgkin lymphoma-unfavorable clinical stage I and II","volume":"39","author":"Roberts","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0011","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2014.59.4853","article-title":"Pediatric Hodgkin lymphoma","volume":"33","author":"Mauz-K\u00f6rholz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0012","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2012.45.3266","article-title":"Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD95","volume":"31","author":"D\u00f6rffel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0013","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0014","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2010-05-285379","article-title":"BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: A report from the Children's Oncology Group","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0015","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ijrobp.2016.07.015","article-title":"Predictive factor analysis of response-adapted radiation therapy for chemotherapy-sensitive pediatric Hodgkin lymphoma: Analysis of the Children's Oncology Group AHOD 0031 trial","volume":"96","author":"Charpentier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): A report from the Children's Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0017","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0018","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0019","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1997.15.8.2769","article-title":"Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study","volume":"15","author":"Weiner","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0020","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0021","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00043426-200606000-00008","article-title":"POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: A report from the Children's Oncology Group","volume":"28","author":"Kung","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0022","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2014.10.042","article-title":"Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): A report from the Children's Oncology Group","volume":"92","author":"Dharmarajan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: Issues in delineating the radiation field in Hodgkin's disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0024","series-title":"Prescribing, recording and reporting photon beam therapy, report 62)","year":"1999"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.canrad.2011.04.003","article-title":"State of the art on dose prescription, reporting and recording in intensity-modulated radiation therapy (ICRU report no. 83)","volume":"15","author":"Gr\u00e9goire","year":"2011","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0026","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0027","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.prro.2014.05.003","article-title":"International Lymphoma Radiation Oncology Group. Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"5","author":"Hodgson","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0028","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: An overview of International Lymphoma Radiation Oncology Group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0029","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2019.02.001","article-title":"The optimal use of imaging in radiation therapy for lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"104","author":"Mikhaeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0030","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0031","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-007-0356-9","article-title":"Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi","volume":"86","author":"Rigacci","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.adro.2017.01.006","article-title":"Importance of baseline PET\/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma","volume":"2","author":"Figura","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0033","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1148\/radiology.160.3.3737899","article-title":"Hodgkin disease: Contributions of chest CT in the initial staging evaluation","volume":"160","author":"Castellino","year":"1986","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0034","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-8-22","article-title":"Hodgkin's lymphoma emerging radiation treatment techniques: Trade-offs between late radio-induced toxicities and secondary malignant neoplasms","volume":"8","author":"Cella","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0035","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ijrobp.2010.05.035","article-title":"Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage Hodgkin lymphoma in female patients","volume":"81","author":"Weber","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0036","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of poton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0037","first-page":"1384","article-title":"Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132:1635-1646","volume":"133","author":"Dabaja","year":"2019","journal-title":"Erratum in: Blood"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0038","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.prro.2019.05.009","article-title":"Comparison of techniques for involved-site radiation therapy in patients with lower mediastinal lymphoma","volume":"9","author":"Everett","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0039","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.prro.2019.01.006","article-title":"Clinical intensity modulated proton therapy for Hodgkin lymphoma: Which patients benefit the most?","volume":"9","author":"Ntentas","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/COC.0000000000000819","article-title":"Selection of mediastinal lymphoma patients for proton therapy within the Proton Collaborative Group Registry: Concordance with the ILROG guidelines","volume":"44","author":"Tseng","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0041","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0042","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.canrad.2011.05.014","article-title":"Intensity-modulated radiotherapy and involved-node concept in patients with Hodgkin lymphoma: Experience of the Gustave-Roussy Institute","volume":"15","author":"Paumier","year":"2011","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0043","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2014.01.041","article-title":"Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma","volume":"89","author":"Filippi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0044","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/0284186X.2016.1197422","article-title":"Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: Results from the Proton Collaborative Group Registry","volume":"55","author":"Hoppe","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0045","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/pbc.26044","article-title":"Proton therapy for pediatric Hodgkin lymphoma","volume":"63","author":"Wray","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0046","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","article-title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","volume":"28","author":"Hoppe","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0047","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0048","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2017.04.001","article-title":"Pulmonary toxicity following proton therapy for thoracic lymphoma","volume":"99","author":"Nanda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0049","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13014-018-1003-4","article-title":"TEDDI: Radiotherapy delivery in deep inspiration for pediatric patients - A NOPHO feasibility study","volume":"13","author":"Lundgaard","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/0284186X.2014.932435","article-title":"Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold","volume":"54","author":"Petersen","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0051","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.prro.2013.07.015","article-title":"Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose","volume":"4","author":"Charpentier","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0052","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2015.01.013","article-title":"Minimizing late effects for patients with mediastinal Hodgkin lymphoma: Deep inspiration breath-hold, IMRT, or both?","volume":"92","author":"Aznar","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0053","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0054","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.1200\/JCO.2004.00.8763","article-title":"Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: Local disease control with combined-modality therapy","volume":"23","author":"Krasin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0055","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.2014.57.8138","article-title":"Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: A subset analysis of the North American Intergroup E2496 trial","volume":"33","author":"Advani","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0056","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0057","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2016.01.053","article-title":"A comparative evaluation of normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the Childhood Cancer Survivor Study and recent Children's Oncology Group trials","volume":"95","author":"Zhou","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0058","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0059","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1200\/JCO.18.01764","article-title":"Therapy-related cardiac risk in childhood cancer survivors: An analysis of the Childhood Cancer Survivor Study","volume":"37","author":"Bates","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0060","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2020.02.642","article-title":"Long-term outcomes in 10-year survivors of early-stage Hodgkin lymphoma","volume":"107","author":"Bates","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0061","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0062","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0063","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0064","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1667\/0033-7587(2003)159[0161:LCATFH]2.0.CO;2","article-title":"Lung cancer after treatment for Hodgkin's disease: Focus on radiation effects","volume":"159","author":"Gilbert","year":"2003","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0066","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.3324\/haematol.2014.108258","article-title":"Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma","volume":"99","author":"Morton","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0067","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.2013.50.6832","article-title":"Stomach cancer risk after treatment for Hodgkin lymphoma","volume":"31","author":"Morton","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0068","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdu287","article-title":"Pancreatic cancer risk after treatment of Hodgkin lymphoma","volume":"25","author":"Dores","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0069","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin's disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0070","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0071","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0072","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0073","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0074","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1200\/JCO.2005.15.107","article-title":"Stroke as a late treatment effect of Hodgkin's disease: A report from the Childhood Cancer Survivor Study","volume":"23","author":"Bowers","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0075","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jnci\/djp147","article-title":"Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma","volume":"101","author":"De Bruin","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0076","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/annonc\/mdn284","article-title":"A prospective study of pulmonary function in Hodgkin's lymphoma patients","volume":"19","author":"Ng","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0077","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.2013.54.4379","article-title":"Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma","volume":"32","author":"van Nimwegen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0078","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1748-717X-7-224","article-title":"Development of multivariate NTCP models for radiation-induced hypothyroidism: A comparative analysis","volume":"7","author":"Cella","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0079","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1716_bib0080","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/pbc.24968","article-title":"Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma","volume":"61","author":"Huynh-Le","year":"2014","journal-title":"Pediatr Blood Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621026298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621026298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:59:44Z","timestamp":1759744784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621026298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0360301621026298"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.1716","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy Across Pediatric Hodgkin Lymphoma Research Group Protocols: A Report From the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.1716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}